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A 48-year-old man presented complaining of lower abdominal pain, and was diagnosed with invasive
bladder cancer. After neoadjuvant chemotherapy, cystoprostatourethrectomy and ileal conduit diversion
were performed. At 53 years of age, bladder cancer recurred in the upper urinary tract and he underwent
complete urinary tract extirpation. Histological examination revealed an urothelial carcinoma in an ileal
conduit. Three years later, a local recurrence led to combined modality therapy including chemotherapy
and radiotherapy. He is receiving maintenance chemotherapy for metastatic tumors. Urothelial
carcinoma arising in an ileal conduit after radical cystectomy for bladder cancer is infrequently reported.
To our knowledge, only 12 cases, including ours, have been reported.
(Hinyokika Kiyo 55 : 345-348, 2009)















現病歴 : 1998年，浸潤性膀胱癌 (UC，cT3bN0M0，
G2) に対し，術前補助化学療法 (MEC : methotrexate
30 mg/m2 day 1，epirubicin 50 mg/m2 day 2，3，










Fig. 1. Loopography reveals a ﬁlling defect of the
right ureter (black arrow) and the ileal
conduit (white arrow).
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る．
入院時所見 : 身 長 180 cm，体重 72 kg．体温
37.4°C，血圧 158/84 mmHg，脈拍82回/分．右肋骨脊
柱角に叩打痛を認めた．血液検査上，WBC 6,800/
mm，Hb 11.81 mg/dl，BUN 26 mg/dl，Cr 2.8 mg/dl，
CRP 19.0 mg/dl．超音波断層法検査および CT にて




















知し，CT にて骨盤内右側に径約 6 cm 大の腫瘤を認
めた (Fig. 3）．肝・肺を含め他臓器に転移は認めな
かった．尿路上皮癌の局所再発の診断のもと，全身化
学療法 (epirubicin : 50 mg/m2 day 1，cisplatin : 50 mg/
m2 day 2，3) を施行した．抗がん剤投与後 1時間目に
透析を施行した． 2 コース終了時点では PR を得た
が， 3 コース目では NC となったため，gemcitabine





療 (40 Gy) を施行した．その後 9 カ月目に腹壁・肝







Fig. 2. a : Macroscopically, a tumor is located in the
middle of the ureter (black arrow) and at the
blind end in an ileal conduit (white arrow).
b : Microscopic view of the tumor shows
transitional cell carcinoma and ileal muscle
invasion. c : Carcinoma in situ is seen in an
ileal conduit (arrow).
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Fig. 3. Abdominal CT scan shows an intrapelvic
mass 6 cm in diameter.
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mg/body day 1，paclitaxel : 175 mg/m2 day 2) を施行し
た．副作用としては，骨髄抑制 (grade 2），末梢神経
障害 (grade 2），肝機能障害 (grade 1) を認めたが，効
















12例中 9例であり， 9例中 5例は同時発症であり，残
り 4例でも上部尿路再発から回腸導管内再発までは平
均1.8年であった．自験例以外の11例の再発部位は尿




























































Soloway, et al. 71/M Yes Ureteroileal anastomosis 1.5 0 TCC TCC 4 yr DOD
Soloway, et al. 53/M Yes Ureteroileal anastomosis 1 0 TCC TCC 4 yr DOD
Grabstald, et al. 52/M No Stoma 4 ― Carcinoma Carcinoma 4 yr NED
Banigo, et al. 69/M Yes Ureteroileal anastomosis 3 1 TCC TCC 4 yr NED
Allan, et al. 56/M Yes Ureteroileal anastomosis 1 0 TCC TCC Unexplained
Wajsman, et al. 57/M Yes Ileal loop 6 3 TCC TCC 7 yr NED
Rubin, et al. 68/F No Ileal loop 6.5 ― TCC TCC 7 yr DOD
Curran, et al. 66/F Yes Ileal loop 4 0 TCC TCC Unexplained
Roberts, et al. 69/F No Ileal loop 0.3 ― TCC TCC 8 mo NED
Rosvanis, et al. 73/M Yes Ureteroileal anastomosis 5 0 TCC TCC 6 yr NED
Shioji, et al. 67/M Yes Ureteroileal anastomosis 0.9 0.5 TCC TCC 1.5 yr DOD
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